The Indian Council of Medical Research (ICMR) has taken a significant step in the fight against malaria by licensing a new multi-stage vaccine called AdFalciVax to five companies. This includes Hyderabad-based firms Indian Immunologicals Limited and Biological E Limited alongside TechInvention Lifecare, Panacea Biotec, and Zydus Lifesciences. The goal is ambitious: to eliminate malaria entirely by 2030.
AdFalciVax targets the malaria parasite, Plasmodium falciparum, at various stages of its lifecycle. This approach is promising because it can prevent the parasite from invading the liver and spreading in the bloodstream, all with just a single dose.
Preclinical trials on the vaccine have shown both safety and effectiveness. Senior public health officials report excellent results in animal and lab studies.
The Vaccine’s Unique Design
Unlike traditional vaccines that use weakened or dead parasites, AdFalciVax incorporates a harmless protein from the malaria parasite, which is produced by a bacteria commonly used in cheese-making. This unique approach allows for a robust immune response against malaria.
Developed by the Regional Medical Research Centre in Bhubaneswar, the vaccine aims to combat the deadliest malaria strains and reduce community transmission. India’s goal is to have zero indigenous malaria cases by 2027, as outlined in the National Framework for Malaria Elimination.
Progress in Malaria Control
India has made impressive strides in malaria control. According to the World Malaria Report 2024, malaria cases dropped significantly from 6.4 million in 2017 to around 2 million in 2023. Deaths fell from 11,100 to 3,500 in the same period. Last year, over 122 districts reported no cases, marking a significant improvement. India has also moved out of the WHO’s High Burden to High Impact category, showcasing its effective malaria control strategies.
Ongoing Challenges and Solutions
Despite the progress, malaria remains a concern in areas like Odisha, Chhattisgarh, and Jharkhand, particularly in tribal regions. Access to healthcare is limited in these hotspots. The Asia Pacific Leaders Malaria Alliance (APLMA) highlights that malnutrition and cross-border transmission complicate efforts to eliminate the disease.
Experts suggest that AdFalciVax could be vital in reducing P. falciparum infections and preventing outbreaks. Combining the vaccine with existing “Test, Treat, Track” strategies could further accelerate elimination efforts.
An official statement from the Ministry of Health and Family Welfare emphasizes that the introduction of this indigenous vaccine is a critical step in transforming malaria control efforts.
Understanding Malaria
Malaria is caused by parasites spread through the bites of infected female Anopheles mosquitoes. Symptoms include fever, headache, and chills, appearing 10 to 15 days after infection. If untreated, malaria can lead to severe illness and even death.
While the disease doesn’t spread directly from person to person, it can be transmitted through blood transfusions or contaminated needles. Plasmodium falciparum is noted as the most dangerous species, highlighting the importance of prevention.
Preventative Measures
To keep malaria at bay, avoiding mosquito bites is crucial. Here are some effective strategies:
- Use mosquito nets at night.
- Apply insect repellents.
- Limit outdoor activity during dusk and dawn in high-risk areas.
- Keep your surroundings clean, especially in backyards.
- Ensure any water used in coolers is clean.
With the launch of the AdFalciVax and ongoing health initiatives, there is hope that India could soon leave behind a disease that has historically wreaked havoc on its population.
For more information on malaria and its prevention, check out World Health Organization.
Source link
MALARIA VACCINE IN INDIA, ICMR, MALARIA CAUSES, MALARIA PRECAUTIONS, FIRST MALARIA VACCINE, INDIA LICENSES ITS FIRST INDIGENOUS MALARIA VACCINE; HYDERABAD TO LEAD PRODUCTION
